Alzheimer’s Disease (AD) is the most common neurodegenerative disease, affecting 10% of seniors over the age of 65 (1). It was named after Alois Alzheimer, a German scientist who discovered tangled bundles of fibrils where neurons had once been in the brain of a deceased patient in 1907 (2). Beta synuclein is abundant in neurofibrillary lesions of patients with Alzheimer’s Disease. Beta synuclein is suggested to be an inhibitor of alpha synuclein aggregation- protecting the central nervous system from the neurotoxin effects of alpha synuclein (3).
Instructions for Use
Active Mouse Recombinant Beta Synuclein Protein Monomer$400.00 – $1,310.00